Value20212022202320242025TTMSelling/general/admin expenses59.06 M30.16 M41.74 M38.62 M48.64 M57.58 MResearch & development34.79 M36.17 M52.12 M65.3 M117.67 M135.79 MOperating income-93.85 M-66.33 M-93.87 M-103.92 M-166.31 M-193.37 MNon-Operating Income, Total-425 K9.73 M-1.71 M6.16 M-6.33 M-32.29 MInterest expense, net of interest capitalized——700 K2.28 M5.48 M6.13 MNon-Operating Income, excl. Interest Expenses-86 K195 K-543 K8.64 M5.68 M5.76 MUnusual income/expense-339 K9.54 M-1.87 M-4.76 M-17.48 M-44.17 MPretax income-94.19 M-56.8 M-95.73 M-108.68 M-183.79 M-367.37 MEquity in earnings——————Taxes-1.16 M-300 K-4.9 M-1.99 M0—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-93.04 M-56.8 M-95.73 M-108.68 M-183.79 M-237.54 MDiscontinued operations——————Net income-93.04 M-56.8 M-95.73 M-108.68 M-183.79 M-237.54 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-93.04 M-56.8 M-95.73 M-108.68 M-183.79 M-230.54 MBasic earnings per share (Basic EPS)—-1.84-2.44-1.54-2.06-2.5Diluted earnings per share (Diluted EPS)—-1.84-2.44-1.54-2.06-2.42Average basic shares outstanding—30.86 M39.16 M70.46 M89.33 M—Diluted shares outstanding—30.86 M39.16 M70.46 M89.33 M—EBITDA-90.79 M-61.46 M-85.88 M-99.48 M-168.26 M-192.94 MEBIT-94.3 M-64.64 M-89.05 M-102.01 M-166.44 M-193.53 MCost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)2.62 M3.18 M3.16 M1.25 M-1.82 M591 K
Definium Therapeutics, Inc. - Common Shares
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.